{
  "variants": [
    {
      "gene": "SNCA",
      "protein_change": "A30P",
      "variant_string": "SNCA A30P",
      "functional_evidence_aim": "Pathogenic",
      "steps": {
        "step1": {
          "judgment": "Yes",
          "details": "The paper states that SNCA mutations cause familial Parkinson's disease and dementia with Lewy bodies, establishing the disease mechanism."
        },
        "step2": {
          "judgment": "Yes",
          "details": "Phospholipid binding and filament assembly assays are directly linked to SNCA's role in Lewy body formation."
        },
        "step3": {
          "step3a": {
            "judgment": "No",
            "details": "The paper does not explicitly describe controls for A30P in the current study; only comparisons to wild-type are mentioned."
          },
          "step3b": {
            "judgment": "Yes",
            "details": "Phospholipid binding and filament assembly are established methods in SNCA research."
          },
          "step3c": {
            "judgment": "No",
            "details": "No variant controls (e.g., known pathogenic/benign variants) are explicitly used in the current study for A30P."
          }
        },
        "step4": {
          "step4a": {
            "judgment": "No",
            "details": "No statistical analysis or OddsPath calculation is provided for A30P in the current study."
          },
          "step4b": {
            "judgment": "Yes",
            "details": "Total benign/pathogenic controls: <10 (wild-type and A53T referenced as controls for E46K, not A30P)."
          }
        },
        "final_evidence": "PS3_supporting"
      }
    },
    {
      "gene": "SNCA",
      "protein_change": "A53T",
      "variant_string": "SNCA A53T",
      "functional_evidence_aim": "Pathogenic",
      "steps": {
        "step1": {
          "judgment": "Yes",
          "details": "The paper explicitly states that A53T is a pathogenic SNCA mutation associated with Parkinson's disease."
        },
        "step2": {
          "judgment": "Yes",
          "details": "Phospholipid binding and filament assembly assays are relevant to A53T's pathogenic mechanism."
        },
        "step3": {
          "step3a": {
            "judgment": "No",
            "details": "The paper does not describe A53T-specific controls in the current study; only comparisons to wild-type are mentioned."
          },
          "step3b": {
            "judgment": "Yes",
            "details": "Phospholipid binding and filament assembly are established methods in SNCA research."
          },
          "step3c": {
            "judgment": "No",
            "details": "No variant controls (e.g., known pathogenic/benign variants) are explicitly used in the current study for A53T."
          }
        },
        "step4": {
          "step4a": {
            "judgment": "No",
            "details": "No statistical analysis or OddsPath calculation is provided for A53T in the current study."
          },
          "step4b": {
            "judgment": "Yes",
            "details": "Total benign/pathogenic controls: <10 (wild-type and A53T referenced as controls for E46K, not A53T)."
          }
        },
        "final_evidence": "PS3_supporting"
      }
    },
    {
      "gene": "SNCA",
      "protein_change": "E46K",
      "variant_string": "SNCA E46K",
      "functional_evidence_aim": "Pathogenic",
      "steps": {
        "step1": {
          "judgment": "Yes",
          "details": "The paper investigates E46K's role in SNCA dysfunction, linking it to Parkinson's disease mechanisms."
        },
        "step2": {
          "judgment": "Yes",
          "details": "Phospholipid binding and filament assembly assays are used to assess E46K's pathogenic effects."
        },
        "step3": {
          "step3a": {
            "judgment": "Yes",
            "details": "The study compares E46K to wild-type (normal control) and A53T (pathogenic control)."
          },
          "step3b": {
            "judgment": "No",
            "details": "No additional controls are mentioned beyond the comparison to A53T."
          },
          "step3c": {
            "judgment": "Yes",
            "details": "A53T is used as a pathogenic control for E46K in the study."
          }
        },
        "step4": {
          "step4a": {
            "judgment": "No",
            "details": "No statistical analysis or OddsPath calculation is explicitly described for E46K."
          },
          "step4b": {
            "judgment": "Yes",
            "details": "Total benign/pathogenic controls: <10 (wild-type and A53T referenced as controls)."
          }
        },
        "final_evidence": "PS3_supporting"
      }
    }
  ]
}